In 2022, total deaths by suicide and drug overdose declined slightly for the first time in five years, according to a report from Trust for America’s Health.
While some harm reduction advocates want to see OPVEE as commercially available as Narcan, others say the medication is so strong that it’s cruel for the patient.
The justices struggled to decide whether to give a thumbs up or thumbs down to the multi-billion dollar Purdue Pharma bankruptcy deal--a deal meant to compensate victims of OxyContin.
Under the deal, Purdue agreed it owed $8 billion in criminal and civil fines. That deal is at the center of Monday's case because it releases the Sacklers from personal liability.
Supreme Court's decision to review the controversial bankruptcy deal involving the maker of Oxycontin means the settlement will remain on hold at least through December.
Two Washington Post journalists say pharmaceutical companies collaborated with each other — and with lawyers and lobbyists — to create laws to protect the industry. Their new book is American Cartel.
The Sacklers, who own Purdue Pharma, maker of Oxycontin, have maintained they did nothing wrong. People who lost loved ones and years of their lives to opioid addiction believe otherwise.
People who were addicted to OxyContin or lost loved ones who were addicted to the drug expect very little in compensation from the multibillion-dollar Purdue Pharma bankruptcy settlement.
The DOJ is seeking to block implementation of any part of the Purdue Pharma bankruptcy deal until legal challenges are settled. The deal granted Sackler family members immunity from opioid lawsuits.
The decision by a federal bankruptcy judge grants members of the family who own Purdue Pharma, maker of OxyContin, sweeping protection from any liability for the opioid crisis.
With a federal judge poised to approve Purdue Pharma's controversial Chapter 11 plan, the company is working behind the scenes to preempt a legal challenge by the DOJ.
In the Purdue Pharma bankruptcy trial now underway, scrutiny has focused on the Sacklers' demand for immunity from opioid lawsuits that would extend to a vast network of individuals and businesses.
The Purdue Pharma bankruptcy process has focused on financial compensation to creditors, but court records include heartrending personal letters from families ravaged by Oxycontin.
Two divisions of the DOJ argue the deal improperly shelters members of the Sackler family and their associates from liability. States are finalizing a separate deal with other opioid companies.
